Fujirebio Diagnostics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Fujirebio Diagnostics sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials none currently recruiting 11 completed top decile by trial count

Fujirebio Diagnostics: 13 sponsored US clinical trials, none currently recruiting.

Fujirebio Diagnostics sponsors 13 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. The most-studied condition in this pipeline is Breast Cancer, with 1 trials.

Top-decile sponsor footprint

Fujirebio Diagnostics ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

11 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

13 total, page 1 of 1

COMPLETED

Fertility in Healthy Premenopausal Women

NCT02772848
COMPLETED

Blood Collection of Patient Presenting in the ED and Prescribed a BNP

NCT02614209
COMPLETED

A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals

NCT02614170
COMPLETED

A Prospective Longitudinal Breast Cancer Study

NCT02270931
COMPLETED

Study Vitamin D in Healthy Individuals

NCT02250625
COMPLETED

Longitudinal Pancreatic Cancer Study

NCT02250638
COMPLETED

Blood Collection From Heart Failure Patients to Evaluate for Galectin-3 Measurement Differences Using Various Collection Tubes

NCT01980862
COMPLETED

New Biomarkers Evaluating Ovarian Cancer

NCT01466049
TERMINATED

A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer

NCT01591512
COMPLETED

Ovarian Cancer Risk Estimation in Patients With Pelvic Mass

NCT00987649
TERMINATED

Multiple Biomarkers in Undiagnosed Pleural Effusion

NCT00316134
COMPLETED

Risk of Ovarian Cancer in Patients With a Pelvic Mass

NCT00315692
COMPLETED

Survivin Urine mRNA Assay Risk of Bladder Cancer Study

NCT00315653

Therapeutic Areas

Breast Cancer 1
Bladder Cancer 1
Ovarian Cancer 1

How the Fujirebio Diagnostics archive is shaped

13 indexed studies, none listed as recruiting (0% open); 11 completed (85%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Breast Cancer (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Fujirebio Diagnostics: archived-pipeline peers nationwide

Peers matched on 13 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Fujirebio Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%2%4%6%8%10% Total trials Recruiting share Fujirebio DiagnosticsAdaptimmuneAgennixAkili Interactive LabsAlumis10xBio22nd Century Group23andMe3-C Institute for Social Development
Fujirebio Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Fujirebio Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Fujirebio Diagnostics page

13 registered trials is a research-attention snapshot, not an endorsement of Fujirebio Diagnostics or any single study.

  • None of Fujirebio Diagnostics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Breast Cancer is the condition Fujirebio Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fujirebio Diagnostics pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.